By the end of April (the first quarter of 2024), seven new drugs IND for mesenchymal stem cells (excluding hematopoietic stem cells) have been added in China, which have been approved by the Drug Evaluation Center (NMPA) of the State Drug Administration.

Recently, IQVIA, a global company in the field of life sciences, released a research report on the current status and future trends of cell and gene therapy.

From January to April 2024, a total of 5 CGT therapies were approved and put on the market worldwide, including 3 cell therapies and 2 gene therapies.

Recently, the Guangdong Provincial Health Commission took the lead in establishing China's first provincial stem cell clinical research quality control center in China.